Immutep: Efti With Pembrolizumab Continue To Show Early Signs Of Antitumour Activity

Immutep Limited (IMMP) reported new interim data from 2nd line NSCLC patients in the phase II TACTI-002 trial. This part of TACTI-002 (Part B) evaluates the company's lead product candidate, eftilagimod alpha in combination with MSD's KEYTRUDA in a total of 36 patients with 2nd line PD-X refractory metastatic NSCLC who were not pre-selected for their PD-L1 status. In the trial, Efti in combination with pembrolizumab is continuing to show encouraging early signs of antitumour activity.

Immutep CSO and CMO, Frederic Triebel, said: "It is encouraging to see efti in combination with pembrolizumab continues to report promising antitumour and safety results in 2nd line NSCLC. In particular, efti in combination with pembrolizumab is demonstrating sustained survival compared with standard of care chemotherapy regimens, and favourable safety and tolerability."

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The U.S. Food and Drug Administration said it now intends to review only a small subset of new emergency use authorization or EUA requests for diagnostic tests. As per an updated COVID-19 test policy with a view to ensure continued access to tests, the regulator further urged developers of all test types seeking marketing authorization to pursue traditional premarket review for most test types. Netflix, Inc. said it is adding a new feature to offer a more personalized mobile games experience on the platform. In a statement, Sophia Yang, Product Manager, Mobile Games, said the company is rolling out the ability to create game handles, with which members will be able to create a unique public username. This can be used across all Netflix games. General Motors Co. has delayed its plan to require employees to return to office many days a week until next year, reports said citing an internal memo signed by CEO Mary Barra. Last week, the company had announced that corporate workers would be required to return to respective offices at least three days a week, beginning later this year, as the COVID-19 pandemic eases.
Follow RTT